Mutations in TBCK, Encoding TBC1-Domain-Containing Kinase, Lead to a Recognizable Syndrome of Intellectual Disability and Hypotonia  by Bhoj, Elizabeth J. et al.
REPORT
Mutations in TBCK, Encoding TBC1-Domain-Containing
Kinase, Lead to a Recognizable Syndrome
of Intellectual Disability and Hypotonia
Elizabeth J. Bhoj,1,2,16,* Dong Li,1,16 Margaret Harr,2 Shimon Edvardson,3,4 Orly Elpeleg,4
Elizabeth Chisholm,5 Jane Juusola,6 Ganka Douglas,6 Maria J. Guillen Sacoto,6 Karine Siquier-Pernet,7
Abdelkrim Saadi,8 Christine Bole-Feysot,9 Patrick Nitschke,10 Alekhya Narravula,11 Maria Walke,12
Michele B. Horner,13 Debra-Lynn Day-Salvatore,13 Parul Jayakar,12 Samantha A. Schrier Vergano,5
Mark A. Tarnopolsky,14 Madhuri Hegde,11 Laurence Colleaux,7 Peter Crino,15 and Hakon Hakonarson1
Through an international multi-center collaboration, 13 individuals from nine unrelated families and affected by likely pathogenic
biallelic variants in TBC1-domain-containing kinase (TBCK) were identified through whole-exome sequencing. All affected individuals
were found to share a core phenotype of intellectual disability and hypotonia, and many had seizures and showed brain atrophy and
white-matter changes on neuroimaging. Minor non-specific facial dysmorphism was also noted in some individuals, including multiple
older children who developed coarse features similar to those of storage disorders. TBCK has been shown to regulate the mammalian
target of rapamycin (mTOR) signaling pathway, which is also stimulated by exogenous leucine supplementation. TBCK was absent in
cells from affected individuals, and decreased phosphorylation of phospho-ribosomal protein S6 was also observed, a finding suggestive
of downregulation of mTOR signaling. Lastly, we demonstrated that activation of the mTOR pathway in response to L-leucine supple-
mentation was retained, suggesting a possible avenue for directed therapies for this condition.Intellectual disability (ID) is a common diagnosis with few
specific disease-directed therapeutic options.1 In some spe-
cific cases when a molecular etiology for ID has been
discovered, especially in the setting of inborn errors of
metabolism, there has been vast improvement in the out-
comes of those individuals.2 The genetic heterogeneity of
ID has traditionally complicated both diagnosis and gene
discovery, leading to a large proportion of affected individ-
uals who never receive a molecular diagnosis. The intro-
duction of agnostic testing, such as genome-wide arrays
and whole-exome sequencing (WES), has accelerated
both discovery of and diagnosis for individuals with ID.
However, such acceleration has also highlighted the need
to identify independent pathogenic variants in the same
gene before a causal link to ID can be established. Using
WES, in nine unrelated families we were able to identify
13 individuals who are affected by ID and hypotonia and
harbor biallelic pathogenic variants in TBC1-domain-con-
taining kinase (TBCK), a gene recently implicated in the
etiology of ID in a single family.3
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sent was obtained. We sequenced DNA from 13 affected
individuals from nine families and their healthy parents
to identify the etiology of their ID and hypotonia. We per-
formed WES if the variant was unknown in the family or
Sanger sequencing if the variant had been identified in
another family member (Table S1). After identifying
TBCK variants in each family, we assembled the cohort
through personal collaborations and the assistance of
GeneMatcher. Each subject sequenced provided written
consent, and all work was performed either in a clinical
laboratory or under an IRB-approved protocol. Variants
previously reported in dbSNP, the 1000 Genomes Project,
and the National Heart, Lung, and Blood Institute
(NHLBI) Exome Sequencing Project (ESP) Exome Variant
Server with a minor allele frequency > 1% were excluded.
Anticipating that synonymous variants are far less likely
to be pathogenic, we focused our variant analysis primar-
ily on nonsynonymous variants, splice-acceptor and
donor-site mutations, and coding insertions/deletions
(indels). When applicable, emphasis was placed on identi-
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Table 1. Characteristics of Individuals with Biallelic Variants in TBCK
Affected Individuals
1-1a 1-2a 2-1 3-1 4-1 4-2
Variants (GenBank:
NM_001163435.2)
Hom
c.1897þ1G>A
Hom
c.1897þ1G>A
Hom
c.831_832insTA
(p.Pro278Tyrfs*18)
Hom c.1652T>C
(p.Leu551Pro)
Het c.[20602A>G];
[803_806delTGAA],
p.[¼];[Met268fsArg*26]
Het c.[20602A>G];
[803_806delTGAA],
p.[¼];[Met268fsArg*26]
Mutation type splice site and
frameshift
splice site and
frameshift
insertion and
frameshift
missense splice site and
frameshift;
frameshift
splice site and
frameshift; frameshift
Consanguinity
reported
þ þ  þ  
Age at last exam died at 5 years 11 years 5 years 11 years 4 years 2 years
Sex male female male male female female
Ethnicity Saudi Saudi Syrian Pakistani mixed European mixed European
Prenatal
findings
decreased fetal
movement,
oligohydramnios
none reported premature
contractions
none reported ventriculomegaly none reported
Development
Motor no sitting rolling at 11 years no sitting mild delay independent
walking
sitting
Speech few words babbling, no words non-verbal mild delay few single words many words
Cognitive severe delay severe delay severe delay mild delay severe delay mild delay
Regression      
Ventilator
dependence
  tracheostomy only   
MRI findings diffuse brain
atrophy, abnormal
white-matter signal
intensity
diffuse brain
atrophy
posterior thinning of
the corpus callosum
and brainstem, ex
vacuo dilation of the
ventricles,
periventricular
leukomalacia
mild prominence
of the lateral
ventricles
none reported none reported
Hypotonia severe severe severe mild to moderate moderate severe
Reflexes delayed reduced absent in lower
extremities
normal reduced reduced
Seizures þ þ þ   
Unusual facial
features
sloped forehead,
bulbous nose,
tented upper lip,
upward slant of
palpebral fissures
tented upper lip,
sloped forehead,
bulbous nose
macrocephaly epicanthal folds,
broad nasal
bridge, deep-set
eyes
 
Other findings abnormal eye
movements,
asthma, eczema
hypothyroidism,
pernicious anemia,
recurrent
candidiasis
strabismus,
nystagmus
autism, bipolar
disorder, high-
arched palate,
broad fingers
and toes, mild
scoliosis
mild macrocephaly 
Abbreviations are as follows: Hom, homozygous; and Het, heterozygous.
a These individuals were previously reported by Alazami et al.3shared between the two affected siblings. In all cases,
filtering WES data for compound-heterozygous, X-linked,
or heterozygous de novo variants did not provide anyThe Amadditional candidate variants. Pathogenic homozygous
or compound-heterozygous variants in TBCK were con-
firmed by Sanger sequencing. Parents were found to beerican Journal of Human Genetics 98, 782–788, April 7, 2016 783
5-1 6-1 6-2 7-1 8-1 9-1 9-2
Hom c.376C>T
(p.Arg126*)
Hom c.1370delA
(p.Asn457Thrfs*15)
Hom c.1370delA
(p.Asn457Thrfs*15)
Hom
c.455þ4 C>G
Hom c.376C>T
(p.Arg126*)
Het c.[(658þ1_
6591)_
(2059þ1_20601)
del];[376C>T],
p[¼];[Arg126*]
Het c.[(658þ1_
6591)_
(2059þ1_20601)
del];[376C>T],
p[¼];[Arg126*]
nonsense frameshift frameshift splice, skipping of
exons 3 and 4
nonsense deletion of exons
7–22; nonsense
deletion of exons
7–22; nonsense
þ þ þ þ   
10 years 12 years 3 years 6 years 12 years 10 years 2 years
female male female male female female male
Hispanic Algerian Algerian Palestinian Puerto Rican and
Dominican
Puerto Rican
and Mexican
Puerto Rican and
Mexican
none reported none reported none reported none reported none reported renal pyelectasis
and hepatic
calcifications
none reported
severe delay sitting walking at 2.5 years sitting sitting no sitting no sitting
no words no words few words few words no words non-verbal non-verbal
severe delay severe delay moderate delay severe delay severe delay severe delay severe delay
þ      
þ    tracheostomy only  
central and cortical
volume loss with
atrophy
discrete
abnormalities of the
periventricular and
bilateral parietal
white matter
discrete
abnormalities of the
periventricular and
bilateral parietal
white matter
discrete
abnormalities of the
periventricular and
bilateral parietal
white matter
abnormal white-
matter intensities
bilateral frontal
white-matter
hyperintensities
on T2-weighted
FLAIR
overall paucity of
white matter, mild
hyperintensity and
central volume loss
on T2-weighted
FLAIR
severe moderate moderate severe severe progressively severe progressively severe
globally decreased present present absent in lower
extremities
reduced not reported not reported
þ    þ  
mildly coarse facies,
synophrys, long
eyelashes,
macroglossia,
microcephaly,
hirsuitism
wide forehead,
bulbous nose, open
mouth, thick lips,
deep palate,
prognathic
mandible
macrocephaly, wide
forehead, short neck
 macrocephaly, very
coarse facial
features, bushy
eyebrows,
macroglossia
metopic ridge,
thick bushy
eyebrows, mildly
high-arched palate
mildly coarse facial
features, hirsute,
epicanthal folds,
long philtrum,
tented upper lip
corneal clouding,
central adrenal
insufficiency and
growth hormone
deficiency, scoliosis
hearing loss,
behavioral
difficulties, delayed
bone age
delayed bone age pectus excavatum,
pulmonic stenosis
possible
mitochondrial
complex III
deficiency, severe
scoliosis, neurogenic
bladder,
hyperthyroidism
small pectus
excavatum, mild
scoliosis, diastasis
recti, clinodactyly,
partial syndactyly of
toes 2 and 3
cryptorchidism, 11
rib pairs, resolved
pelviectasisheterozygous for each of the variants found in their chil-
dren, consistent with an autosomal-recessive model. The
one homozygous missense variant was computationally784 The American Journal of Human Genetics 98, 782–788, April 7, 2predicted to have an functional effect, given that it
contains a highly conserved nucleotide (phyloP score ¼
8.35 [20.0;10.0]), encodes an amino acid highly016
Figure 1. Diagram of TBCK with Reported Variants and Facial Features and Brain Imaging of Affected Individuals
(A) A diagram of TBCK includes known domains and the variants present in the individuals described in this report. Abbreviations are as
follows: Hom, homozygous; and Comp Het, compound heterozygous.
(B–D and G–I) Facial features of individuals 8-1 (B) and 2-1 (G), affected siblings 4-1 (C) and 4-2 (H), and affected siblings 6-1 (D) and 6-2
(I). Individuals 8-1 and 2-1 have coarse features with significant macroglossia, and individuals 4-1 and 4-2 have no significant facial dys-
morphisms. Note the mild dysmorphic features, including a wide forehead, bulbous nose, open mouth with macroglossia, thick lips,
deep palate, and prognathic mandible, in individual 6-1 and the wide forehead and short neck in individual 6-2.
(E, F, and I–K) Brain MRI of individuals 6-1 (E), 6-2 (J), and 7-1 (F and K) demonstrates discrete abnormalities of the periventricular and
parietal white matter in both studies.conserved up to C. elegans (considering 13 species), has
a moderate physicochemical difference between Leu
and Pro (Grantham distance ¼ 98 [0–215]), is found in
the Rab-GTPase-TBC domain, and is predicted to be dele-
terious by SIFT (score ¼ 0.01, median ¼ 3.35) and disease
causing by MutationTaster (p value ¼ 1).
These 13 affected individuals all share a core phenotype
of ID and hypotonia in addition to variable expressivity
of other features as summarized in Table 1 (see also
Figure 1A). A few individuals demonstrated facial features
reminiscent of a storage disease (e.g., macroglossia and
coarse facies), but it was not a universal feature and
might develop as the children age. Several individuals
demonstrated other mild facial anomalies, but none that
appeared diagnostic (Figures 1B–1D and 1G–1I). Seven in-
dividuals from five families had seizures, which were often
refractory to pharmacologic management. Development
ranged from profound to mild developmental delay, and
only one individual demonstrated regression. Brain MRIThe Amshowed a thin corpus callosum and brainstem, ex vacuo
dilation of the lateral ventricles, periventricular leukomala-
cia, and white-matter changes ranging from non-specific
to a picture of leukodystrophy (Figures 1E, 1F, 1J, and
1K). The following features were found in a minority of
individuals, so their relevance to the phenotype remains
unclear: hyperthyroidism, hypothyroidism, pernicious
anemia, suspected immune deficiency, corneal clouding,
scoliosis, central adrenal insufficiency, growth hormone
deficiency, and profound bilateral hearing loss.
Although all 13 individuals demonstrated develop-
mental delays, the least-affected individual (individual
3-1) had the only missense variant in our cohort and
showed only mild delays and minimal MRI abnormalities.
The other individuals all had variants suspected to lead to
significant protein truncation from splice-site substitu-
tions, small insertions, small deletions, or multi-exonic de-
letions and subsequently appeared to have a more severe
phenotype. It is likely that additional individuals witherican Journal of Human Genetics 98, 782–788, April 7, 2016 785
Figure 2. Western Blot Demonstrates
Absent TBCK and Decreased mTOR
Signaling in Lympoblastic Cells of
Affected Individuals
Western blots of immortalized lympho-
cytes (LCLs) from a control individual
and individuals 1-1 and 1-2; both affected
individuals have homozygous frameshift
variants.
(A) Top: TBCK levels were lower in pro-
band LCLs (from individual 1-1 and 1-2)
than in control LCLs. Middle: levels of
mTOR and non-phosphorylated S6 were
unchanged, but levels of PS6 isoform
Ser235/236 were lower in LCLs with
mutant TBCK than in control cells. Bot-
tom: GAPDHwas used as a loading control.
(B) Relative densitometry graph shows the levels of PS6 isoform Ser235/236 in fibroblasts with mutant TBCK (from individuals 1-1 and
1-2) and control fibroblasts across independent western blots in triplicate. Lines depict the SE. Cells were provided by Fowzan S. Alkuraya
and colleagues of the King Faisal Specialist Hospital and Research Center.pathogenicmissense variants in the population have yet to
be identified given that they would have a milder pheno-
type, and their variant would be less easily recognized as
disease causing. Additionally, in one family (individuals
9-1 and 9-2), the combination of a nonsense variant and
a multi-exon deletion required both exome sequencing
and a genome-wide array to confirm the diagnosis.
Clinical diagnosis was also complicated by the signifi-
cant variability in presentation, even within the sibling
pairs we identified, and the lack of a clear environmental
or therapeutic intervention as an explanation. Also,
although multiple individuals in this series showed dys-
morphic features, there does not appear to be a clearly
identifiable facial gestalt associated with this syndrome.
Coarse facial features did appear to develop in middle
childhood in some individuals, but this was also non-spe-
cific. Similarly, brain MRI appeared non-specific and might
have mimicked a leukodystrophy process in the more
severely affected individuals. These features of the syn-
drome highlight the need for a clinically agnostic diag-
nostic tool, such as exome sequencing or gene panels, to
confirm the diagnosis.4 Previous diagnoses considered for
these individuals included static encephalopathy, lyso-
somal-storage disease, leukodystrophy, and mitochondrial
disorder, but no single alternate differential diagnosis was
clearly favored throughout the cohort. Also complicating
diagnosis, this disease is not restricted to one geographic
region, given that these affected individuals have diverse
ethnic backgrounds. However, there does appear to be
a common variant, c.376C>T (p.Arg126*) (GenBank:
NM_001163435.2), reported in the three Hispanic fam-
ilies, suggesting a founder effect in this population.
TBCKwas named for the Tre-2, Bub2p, andCdc16p (TBC)
1 domain and the protein kinase domain found within the
encoded protein. Interestingly, TBCK has recently been
implicated in the regulation of mammalian target of rapa-
mycin (mTOR) signaling, given that knockdown of TBCK
decreases the transcription of mTOR complex (mTORC)
proteins and downregulates mTOR signaling.5 mTOR is a786 The American Journal of Human Genetics 98, 782–788, April 7, 2proline-directed serine threonine protein kinase; activation
of the mTOR pathway leads to phosphorylation of ribo-
somal protein S6.Many developmental disorders, including
tuberous sclerosis (MIM: 191100) and PTEN-related disor-
ders (MIM: 158350), are associated with aberrant mTOR
signaling, and mTOR signaling has been shown to play a
role in structural brain malformations, epilepsy, autism,
and ID.6,7 One of the many activators of the mTOR
pathway has been shown to be leucine, one of the essential
amino acids, throughmTORC1.8 The effects of leucine sup-
plementation onmTOR activation have been studied in the
context of adipogenesis, increased muscle mass, and dia-
betes control.9,10
To evaluate the functional consequences of the TBCK
variants, we used western blotting to assess the amount
of TBCK in immortalized lymphoblastoid cell lines
(LCLs) from one healthy control subject and two individ-
uals (1-1 and 1-2) with homozygous TBCK variants pre-
dicted to lead to a frameshift. Blots were probed with a
polyclonal anti-TBCK antibody raised against the C-termi-
nal region within amino acids 457–694. Whereas TBCK
was clearly detectable as a single band in control LCLs,
no protein was found in cell extracts from the affected in-
dividuals’ LCLs (Figure 2A). Western blotting demon-
strated mTOR-pathway signaling in LCLs and in cultured
fibroblasts from one other individual (2-1) with a different
predicted frameshift TBCK variant. Levels of non-phos-
phorylated and phosphorylated S6 (PS6) isoform Ser235/
236 were assessed in triplicate. Densitometry of the blots
revealed that PS6 levels were, on average, 78% (range ¼
76%–82%, SEM5 6) lower in LCLs harboring TBCKmuta-
tions than in control LCLs (p < 0.05; Figure 2B) and that
PS6 Ser235/236 levels were, on average, 36% (range ¼
31%–41%, SEM5 5) lower in fibroblasts harboringmutant
TBCK than in control fibroblasts (p < 0.05; Figure 3A);
a decrease in PS6 (Ser240/244) was observed as well
(Figure 3B). There was no change in the level of non-phos-
phorylated S6 or mTOR proteins in either LCLs or fibro-
blasts containing TBCKmutations. The addition of leucine016
Figure 3. Western Blots Demonstrate
Decreased mTOR Signaling in Fibroblasts
of Affected Individuals
Levels of PS6 isoforms Ser235/236 (A) and
Ser240/244 (B) were lower in fibroblasts
harboring mutant TBCK (from individual
2-1) than in control cells. The blot demon-
strates that levels of PS6 isoform Ser235/
236 were, on average, 36% (range 31%–
41%, SEM 5 5) lower in fibroblasts with
mutant TBCK than in control fibroblasts
(p < 0.05). There was no change in the
level of non-phosphorylated S6 or mTOR
in either LCLs or fibroblasts containing
TBCK mutations. GAPDH was used as a
loading control.(600 mg/ml), a known nutrient stimulator of mTOR activa-
tion, to the culture media of fibroblasts from individual 2-1
induced an upregulation of basal mTOR signaling, as evi-
denced by increased levels of PS6 (24% 5 4%; p < 0.05;
Figure 4).
The precise function of TBCK has not been fully eluci-
dated, but previous studies have shown that TBCK is
downregulated by rapamycin and that RNAi directed
against TBCK increases STAT3 phosphorylation and
decreases ERK1/2 phosphorylation.11,12 In addition,
depleting TBCK at the cellular level leads to decreased
cell proliferation, smaller cells, and aberrant actin organi-
zation.5 Given that we have demonstrated the absence of
TBCK in multiple affected individuals’ cells, it is likely
that disruption of these processes causes their phenotypes.
We were able to show that cells from these individuals
demonstrated reduced phosphorylation of the Ser235/Figure 4. Western Blot Demonstrates that Leucine Normalizes
mTOR Signaling in Fibroblasts of Affected Individuals
EnhancedmTOR signaling in TBCKmutant fibroblasts (individual
2-1) with the addition of exogenous L-leucine (600 mg/ml). The
western blot demonstrates increased levels of PS6 (24 5 4%; p <
0.05). GAPDH was used as a loading control.
The Am236 isoform of PS6, suggesting that reduced mTOR
signaling is a pathogenic mechanism. This would add
TBCK-related ID syndrome to the list of other neurodeve-
lopmental disorders that have been associated with aber-
rant mTOR signaling: neurofibromatosis type 1 (MIM:
162200), tuberous sclerosis, PTEN-related disorders, and
fragile X syndrome (MIM: 300624).6,13
There are few targeted therapies for neurodevelopmen-
tal disorders, but by elucidating the molecular and
cellular pathology in these individuals, we were able to
hypothesize a targeted therapeutic for restoring mTOR
signaling. When leucine was added to the cells of the
affected individual, it was able to increase the mTOR
signaling by using increased phosphorylation of PS6
Ser235/236 as a proxy. This shows that there is a TBCK-
independent pathway for leucine to stimulate the
mTOR pathway, which could be utilized for therapeutic
effect in these individuals. Leucine supplementation is
already clinically available for certain metabolic disorders
and has a wide therapeutic range (as reviewed in Pedroso
et al.14).
In conclusion, we have reported a series of 13 individuals
who are from nine unrelated families, harbor biallelic mu-
tations in TBCK, and display overlapping features of ID
and hypotonia. We propose that this condition be named
TBCK-related ID syndrome. A potential avenue for thera-
peutic intervention was demonstrated by TBCK-indepen-
dent upregulation of mTOR signaling with the addition
of leucine to the culture media in affected cells. Future
work will include initiating a registry for individuals with
TBCK-related ID syndrome to further delineate the natural
history of the syndrome and test targeted therapies for the
condition.Supplemental Data
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